VERU INC. - COMMON STO

Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022

24 Oct 2022 08:30:00 By Nasdaq GlobeNewswire

Veru to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022

13 Oct 2022 08:30:00 By Nasdaq GlobeNewswire

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

04 Oct 2022 16:30:00 By Nasdaq GlobeNewswire

Veru to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th, 2022

21 Sep 2022 08:30:00 By Nasdaq GlobeNewswire

Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

19 Sep 2022 12:15:00 By Nasdaq GlobeNewswire

Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

07 Sep 2022 13:45:00 By Nasdaq GlobeNewswire

Veru to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12th, 2022

06 Sep 2022 08:30:01 By Nasdaq GlobeNewswire

Veru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration

22 Aug 2022 08:30:00 By Nasdaq GlobeNewswire

Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients

19 Aug 2022 08:30:00 By Nasdaq GlobeNewswire

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

12 Aug 2022 16:30:00 By Nasdaq GlobeNewswire

Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories

11 Aug 2022 06:30:00 By Nasdaq GlobeNewswire

Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 11th International Conference on Emerging Infectious Diseases (ICEID) on August 7-10, 2022

09 Aug 2022 08:30:01 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2022 Third Quarter Financial Results, Host Conference Call on August 11th

28 Jul 2022 08:30:01 By Nasdaq GlobeNewswire

European Medicines Agency’s Emergency Task Force Has Initiated the Review of Veru's Sabizabulin Treatment for Hospitalized COVID-19 Patients for Emergency Use in European Union Countries

27 Jul 2022 11:00:00 By Nasdaq GlobeNewswire

UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients

25 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

12 Jul 2022 16:30:00 By Nasdaq GlobeNewswire

Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients

06 Jul 2022 07:30:45 By Nasdaq GlobeNewswire

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

24 Jun 2022 16:30:00 By Nasdaq GlobeNewswire

Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDS

07 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

06 Jun 2022 06:30:00 By Nasdaq GlobeNewswire